BioLineRx Ltd. (BLRX)
NASDAQ: BLRX · Real-Time Price · USD
0.440
-0.014 (-2.98%)
Nov 7, 2024, 11:09 AM EST - Market open
BioLineRx Employees
BioLineRx had 79 employees as of December 31, 2023. The number of employees increased by 30 or 61.22% compared to the previous year.
Employees
79
Change (1Y)
30
Growth (1Y)
61.22%
Revenue / Employee
$215,797
Profits / Employee
-$381,253
Market Cap
39.47M
Employees Chart
Related Stocks
Company Name | Employees |
---|---|
CareCloud | 3,600 |
Adagio Medical Holdings | 85 |
NextCure | 82 |
SAB Biotherapeutics | 57 |
Surrozen | 42 |
Lantern Pharma | 21 |
AEON Biopharma | 10 |
Lexaria Bioscience | 5 |
BLRX News
- 2 days ago - BioLineRx Announces Oral Presentation on Data from Phase 1 Clinical Trial Evaluating Motixafortide for CD34+ Hematopoietic Stem Cell Mobilization for Gene Therapies in Sickle Cell Disease at ASH 2024 - PRNewsWire
- 22 days ago - BioLineRx Announces USPTO Allowance of New Composition of Matter Patent on Motixafortide - PRNewsWire
- 7 weeks ago - BioLineRx Launches 'Mobilization Matters': A Digital Resource for People with Multiple Myeloma Preparing for Stem Cell Collection - PRNewsWire
- 2 months ago - BioLineRx Ltd. (BLRX) Q2 2024 Earnings Call Transcript - Seeking Alpha
- 3 months ago - BioLineRx Reports Second Quarter 2024 Financial Results and Recent Corporate and Portfolio Updates - PRNewsWire
- 3 months ago - BioLineRx to Report Second Quarter 2024 Results on August 15, 2024 - PRNewsWire
- 5 months ago - BioLineRx Announces Clinical Trial Agreement with St. Jude Children's Research Hospital, Inc. to Evaluate Motixafortide for CD34+ Hematopoietic Stem Cell (HSC) Mobilization For Gene Therapy Applications in Sickle Cell Disease (SCD) - PRNewsWire
- 5 months ago - BioLineRx Ltd. (BLRX) Q1 2024 Earnings Call Transcript - Seeking Alpha